title: Mosapride in gastrointestinal disorders.
abstract: Mosapride was effective in improving overall symptoms in patients with gastrointestinal disorders, including chronic gastritis, gastro-oesophageal reflux disease and functional dyspepsia. Mosapride was more effective than teprenone in improving gastric stasis symptoms and gastric pain after 2 weeks of therapy (p < 0.001) in an open-label trial in 1042 patients with functional dyspepsia. Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment. Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.
authors.affiliation: Wolters Kluwer Health,Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Monique P
authors.initials: MP
authors.lastname: Curran
authors.forename: Dean M
authors.initials: DM
authors.lastname: Robinson
mesh_terms: D001549:Benzamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004415:Dyspepsia / Q000188:drug therapy; D005756:Gastritis / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride